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Abstract
Objective: The Escala Study evidenced that the administration of glatiramer acetate for relapsing-remitting multiple
sclerosis improved the spasticity of patients previously treated with interferon-β. However, whether such an improvement
was translated into cost savings remained unclear. We therefore conducted a cost analysis of glatiramer acetate versus
interferon-β in these patients with multiple sclerosis and spasticity.
Methods: This cost analysis encompassed data from the observational Escala Study, which included patients with
relapsing-remitting multiple sclerosis and spasticity whose treatment had been switched from interferon-β to
glatiramer acetate. Costs prior to starting glatiramer acetate (interferon-β period) were compared to the subsequent six
months on glatiramer acetate (glatiramer acetate period). The analysis was carried out following the recommendations
for conducting pharmacoeconomic studies and from the Spanish National Health System perspective. Costs associated
with multiple sclerosis treatment, spasticity treatment and relapse management were expressed in 2014 euros (€); a
7.5 % discount was applied—when needed—as stipulated in Spanish law.
Results: The management of relapsing-remitting multiple sclerosis, spasticity and relapses accounted for a 6-month
cost per patient of 7,078.02€ when using interferon-β and 4,671.31€ when using glatiramer acetate. Switching from
interferon-β to glatiramer acetate therefore represented a cost saving of 2,406.72€ per patient in favour of glatiramer
acetate, which resulted from savings in treatment costs, relapse management and spasticity treatment of 1,890.02€,
430.48€ and 86.21€, respectively. The ratio of the costs during interferon-β was 1.5 times the costs during glatiramer
acetate; thus, a fixed budget of 5,000,000€ would enable 1,070 patients to be treated with glatiramer acetate and only
706 patients with interferon-β.
Conclusions: The treatment of relapsing-remitting multiple sclerosis with glatiramer acetate entailed cost savings when
compared to interferon-β in patients with spasticity, which not only resulted from its lower costs of therapy and relapse
management but also from its favourable effect on reducing spasticity. Thus, glatiramer acetate may be regarded as a
more efficient alternative than interferon-β from the perspective of the Spanish National Health System.
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Background
Multiple sclerosis (MS) is a chronic, progressive, neuro-
degerenative, auto-immune and disabling disease of the
central nervous system. Its most commonly diagnosed
type is relapsing-remitting multiple sclerosis (RRMS),
which is associated with a repeating pattern of relapses
followed by a period of remission [1]. MS is the most
common cause of neurological disability in young adults
worldwide [2], with a widely variable prevalence ranging
from 50 to 125 cases per 100,000 people/year in Spain
[3–6]. MS has a considerable impact on patients’ quality
of life, particularly during relapses and as the disease
progresses [7]. It additionally represents a large eco-
nomic burden for the patients, their careers, and the
health service [8].
Drug therapies that are able to reduce the number of
relapses and/or slow disease progression in RRMS are
known as disease-modifying therapies (DMTs); a DMT
is typically initiated as soon as a diagnosis of RRMS is
confirmed. First-line basic therapy is distinguished from
second-line escalation therapies. Usually, the treatment
is started with basic therapeutics and the patient is mon-
itored clinically with subsequent magnetic resonance
imaging (MRI). In case of stable disease and well-
tolerated treatment, the therapy is continued. In case of
ongoing clinical and/or radiological disease activity and/
or relevant side effects, an escalation therapy can be ini-
tiated. In general, patients with ≥1 relapse per year,
absence of complete recovery from relapses, sustained
disability progression of ≥1 and MRI progression, with
or without clinical signs, are considered as ‘treatment
non-responders’, justifying the transition from basic to
escalation therapy [9]. DMTs are basic therapeutics that
include interferon-β (Avonex®, Betaferon®/Betaseron® and
Rebif®) and glatiramer acetate (Copaxone®), which are
immunomodulators used as first-line therapeutics with
more than 20 years of experience. They reduce the annu-
alized relapse rate by approximately 30 % and do not
cause severe side effects [10]. At this time, there are three
more oral drugs available: teriflunomide (Aubagio®), dime-
til fumarate (Tecfidera®) and fingolimod (Gilenya®). The
first two drugs constitute first-line treatments, but fingoli-
mod is licensed by the European Medicines Agency for
RRMS patients with highly active or rapidly evolving
severe RRMS, as described in the Summary of Product
Characteristics [11].
The emergence of DMTs such as interferon-β or gla-
tiramer acetate has considerably improved the course
of RRMS. Their administration has enabled relapse fre-
quency to be reduced and disease progression to be
slowed [12, 13]. However, MS patients may still experi-
ence other undesirable effects of the disease such as
spasticity, which often appears as the clinical course
evolves and may affect up to 84 % of patients [14].
Spasticity arises from hyperactive stretch reflexes caused
by damages in the brain and spinal cord [15], which result
in increased muscle tone, spasms and/or pain that may
affect patients’ movements and sphincter control [16]. As
spasticity worsens, patients face increasing difficulties to
perform activities of daily living and their degree of dis-
ability increases considerably. Thus, the administration of
symptomatic treatment needs to be considered as a part
of MS management, after considering the extent and im-
pact of patients’ spasticity and potential exacerbating fac-
tors [16–18]. Special attention should be paid to the
administration of therapies that may affect spasticity,
which also includes the treatment of MS with interferon-β
[16, 17]. Indeed, increased spasticity has been observed in
13–15 % of MS patients receiving interferon-β [19, 20],
mainly in those with pronounced spasticity before treat-
ment administration [21].
However, the data available on glatiramer acetate
administration have not revealed any worsening of spas-
ticity [19, 22]. Furthermore, the results of a pilot study
that specifically addressed the effect of glatiramer acetate
on spasticity in patients with RRMS not only supported
the absence of spasticity increase but they also suggested
spasticity improvements in patients previously treated
with interferon-β [23]. Based on these results, we
conducted a larger observational study—the Escala
Study—to provide further insight into the effect of glatir-
amer acetate on spasticity in patients switching from
interferon-β [24]. The results obtained also supported
the achievement of spasticity improvements in terms of
muscle tone, spasm frequency and pain, which were
apparent from the third month on glatiramer acetate
and remained until at least the sixth month of treatment.
These improvements could additionally lead to cost sav-
ings derived from a more reduced need for spasticity
treatment, representing a substantial benefit for the
National Health System and contributing to its sustain-
ability. Nevertheless, whether such improvements really
translate into cost savings still remained to be assessed.
In light of the above, we conducted a cost analysis of
glatiramer acetate versus interferon-β in patients with
RRMS and spasticity within the context of the Escala




This cost analysis encompassed data from the observa-
tional Escala Study [24], which included patients with
RRMS recruited from 27 Spanish hospitals. Patients
were between 18 and 60 years of age, had confirmed
spasticity and MS treatment switched from interferon-β
to glatiramer acetate (Copaxone®, Teva Pharmaceuticals
Ltd., London, United Kingdom), which must have been
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administered for at least 24 weeks under clinical prac-
tice conditions. Investigators obtained all the study data
from direct review of patients’ medical charts, including
information on patients’ clinical follow-up and spasti-
city assessments conducted every three months after
starting glatiramer acetate. Patient data were collected
from September 2009 to January 2011. A total of 75
patients were recruited, seven of whom were screening
failures; 68 patients comprised the evaluable popula-
tion. The main reasons for switching from interferon-β
were adverse reactions (55.7 %) and lack of response
(40.5 %). Information on the number of MS relapses
was collected, patients’ disability was assessed accord-
ing to the Kurtzke Expanded Disability Status Scale
(EDSS), and spasticity was evaluated according to the
following specific scales: Penn Spasm Frequency Scale
(PSFS), Modified Ashworth Scale (MAS), Adductor
Tone Rating Scale (ATRS) and Global Pain Score
(GPS); these latter scales were selected to provide an
overall assessment of spasticity and spasticity-related
signs such as spasms, increased muscle tone and pain.
The study was conducted in accordance with the World
Medical Association Declaration of Helsinki, all its
amendments and national regulations. It was also
approved by the ethics committees and all patients gave
their written informed consent.
Since the Escala Study showed spasticity improve-
ments after switching from interferon-β to glatiramer
acetate in all previously-mentioned spasticity scales
[24], a cost-comparison analysis of both therapies was
conducted taking into account the potential impact of
such improvements. In this analysis, patients were their
own control as the cumulative costs prior to starting
glatiramer acetate (interferon-β period) were compared
to the subsequent six months on glatiramer acetate
(glatiramer acetate period).
Perspective, time horizon and discount rate
The analysis was carried out following the recommenda-
tions for conducting pharmacoeconomic studies and
from the Spanish National Health System perspective
[25]. The analysis assumed a time horizon equal to the
follow-up period in the Escala Study, and was thus set to
6 months. The calculations were performed without ap-
plying a discount rate to costs, except for the sensitivity
analysis.
Resource and cost estimation
Resources used during interferon-β and glatiramer acet-
ate periods were identified, measured and quantified
according to data included in the Escala Study database.
We obtained data on the use of DMTs (administration
doses), spasticity treatment (different medicines, doses,
and health care) and relapse management (treatments
and doses). A standard price for each identified resource
was assigned, taking into account the costs associated
with MS treatment, spasticity treatment and relapse
management (Table 1).
Costs of multiple sclerosis treatment
The costs of interferon-β and glatiramer acetate were es-
timated according to their administration doses and unit
costs, and presented as ex-factory prices; missing doses
were not considered for the total costs of treatments.
Drug list prices were taken from the Spanish medicines
database [26] and a 7.5 % discount was applied to drug
prices as stipulated by Spanish law [27].
Costs of spasticity treatment
Costs of spasmolytic drugs were estimated according to
their administration doses and respective unit costs, and
presented as ex-factory prices. Drug list prices were also
taken from the Spanish medicines database [26] and a
7.5 % discount was applied—when needed—to drug prices
as stipulated by Spanish law [27]; no price discount was
needed for generic drugs.
Costs of relapse management
Costs associated with the management of relapses were
estimated according to previously published relapse-
related costs; it included direct treatment and informal
care resource development using a costs-of-illness
method [28].
Cost-analysis
A cost-analysis was conducted taking into account costs
associated with MS treatment, spasticity and relapse
management, and changes in the PSFS, MAS, ATRS,
GPS and EDSS as effectiveness variables. Data on these
scales was retrieved from the Escala Study database. We
programmed a cost model using Microsoft Excel 2013
(Microsoft Corporation, Redmond, Washington).
Sensitivity analysis
A sensitivity analysis was conducted to verify the robust-
ness of the model, which included two univariate ana-
lyses that assessed the impact of parameters with the
most uncertainty: 1) concomitant and spasticity treat-
ments, and 2) annual discount rates for future costs.
The former included the calculation of the economic
impact when considering no concomitant or spasticity
treatment, without taking into account adverse-event-
related costs; the latter included the calculation of costs
when applying annual discount rates of 3 % and 5 %.
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Results
Base case analysis
The Escala Study included 68 evaluable patients with
RRMS and spasticity who had switched from interferon-β
to glatiramer acetate. A summary of patient characteristics
is given in Table 2. All these patients were considered for
the costs analyses presented in this article. We selected
the Escala Study because it was the only study about this
topic that had been performed in Spain; it included infor-
mation from the real-life clinical setting, without any
intervention, and we could therefore take advance of that.
The management of RRMS, spasticity and relapses
accounted for a 6-month cost per patient of 7,078.02€
when using interferon-β and 4,671.31€ when using gla-
tiramer acetate (Table 3). Switching from interferon-β
to glatiramer acetate therefore represented a cost saving
of 2,406.72€ per patient in favour of glatiramer acetate
that resulted from savings in treatment costs, relapse
management and spasticity treatment of 1,890.02€,
430.48€ and 86.21€, respectively (Table 3).
The ratio of the costs during interferon-β was 1.5 times
the costs during glatiramer acetate, which means that a
fixed budget of 5,000,000€ would enable 1,070 patients to
be treated with glatiramer acetate and only 706 patients
with interferon-β (Fig. 1). In addition, treating 1,000
patients with glatiramer acetate would cost 4,671,302.80€,
while this figure would rise to 7,078,024.04€ if they were
treated with interferon-β (Fig. 2).
Sensitivity analysis
Results of sensitivity analysis are presented in Table 4.
The assumption of no concomitant/spasticity treatment
yielded overall 6-month costs of 6,225.96€ and 4,335.94€
during interferon-β and glatiramer acetate treatments,
respectively. When a discount rate of 3 % was applied,
the costs during interferon-β were 6,871.86€ and those
during glatiramer acetate were 4,535.25€. After applying
a discount rate of 5 %, these costs were reduced to
Table 1 Unit costs
Treatment Units/Dosage forms Cost/Unit (2014 ex-factory price) Cost/Unit −7.5%a (2014 ex-factory price)
Disease modifying treatment
Glatiramer acetate 20 mg/ml, 28 prefilled syringes, 1 ml 781.25€ 722.55€
IFN-β 1a sc 44 μcg/0.5 ml, 4 cartridges, 1.5 ml 1,167.21€ 1,079.76€
IFN-β 1a im 30 μcg, 4 prefilled syringes, 0.5 ml 835.82€ 773.13€




Baclofen 10 mg, 1 vial, 5 ml 19.83€ NA†
Clonazepam 60 tablets, 2 mg 2.00€
Diazepam 100 tablets, 5/10 mg 1.30€
Lorazepam 20 tablets, 5 mg 2.00€
Tetrazepam 30 tablets, 50 mg 2.83€
Tizanidine 30 tablets, 2 mg 2.53€
Gabapentin 90 capsules, 300 mg 5.93€
Botulinum toxin 1 vial, 100 IU 159.12€ 147.18€
Relapses cost/patient (direct and
indirect costs included)
One episode 2,609.00€ NA
aThe cost analysis is expressed in 2014 euros (€) and a discount of 7.5 % on treatment prices was applied as stipulated in Spanish law (Royal Decree 8/2010);
†A price discount of 7.5 % was not applied since these are generic drugs
im intramuscular, NA not applicable, sc subcutaneous
Table 2 Summary of patient characteristics at starting
glatiramer acetate (N = 68)
Characteristics Value
Age (years), mean ± SD 41.7 ± 9.5
Female, n (%) 48 (70.6)
Caucasian, n (%) 66 (97.1)
Multiple sclerosis duration (years), mean ± SDa 7.6 ± 5.7
Previous interferon-β for multiple sclerosis, n (%):
IFN-β 1a sc 29 (42.6)
IFN-β 1a im 28 (41.2)
IFN-β 1b 22 (32.4)
Number of relapses from multiple sclerosis
diagnosis, mean ± SD†
4.1 ± 3.4
EDSS score, mean ± SD 3.2 ± 4.1
aMissing data, n = 5; †Missing data, n = 2
EDSS Expanded Disability Status Scale, im intramuscular, sc subcutaneous,
SD standard deviation
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6,740.97€ for interferon-β and 4,448.87€ for glatiramer
acetate.
Discussion
This study supports that the treatment of RRMS with gla-
tiramer acetate entails cost savings derived from reduced
expenses in therapy cost, relapse management and spasti-
city improvement when compared to interferon-β. Indeed,
our study showed an overall 6-month cost per patient of
4,671.31€ during glatiramer acetate treatment and a cost
saving for the Spanish National Health System of 2,406.71€
when compared to interferon-β, which resulted from sav-
ings of 1,890.02€ in disease modifying therapies, 430.48€ in
relapse management and 86.21€ in spasticity treatment.
These cost savings represent additional benefits to the
spasticity improvements that were previously observed in
terms of PSFS, MAS, ATRS and GPS scores after switching
from interferon-β to glatiramer acetate [24]. Added to the
underlying pathophysiology of spasticity, certain external
factors and drugs such as interferon may exacerbate the
existing condition; hence, their awareness is crucial as part
of an effective management of spasticity. Furthermore, the
evidence for the effectiveness of glatiramer acetate in pre-
venting spasticity in naïve patients and in those switching
from interferon should not be ignored [29].
Apart from the evidence on the clinical benefits of
therapies, national health services also need to take into
account their respective budget impact to efficiently
allocate the recourses needed for disease management
[30, 31]. Previous economic evaluations carried out in
Spain have reported that the annual costs per patient of
MS during glatiramer acetate may range from 9,439.42€
to 32,250.996€ [32–36], while those during interferon-β
vary from 9,955.74€ to 37,493.45€ [32, 34–37]. In addition,
cost-comparison analyses conducted in our country have
also pointed out that glatiramer acetate represents a less
costly strategy for managing RRMS that may led to sub-
stantial cost savings for the Spanish National Health
System when compared to interferon-β [32, 34–36]. De-
terministic results showed that the expected annual cost
per patient was lower when treated with glatiramer acetate
(13,843€) compared with interferon (15,589€), and the
combined treatment with both interferon and glatiramer
acetate (21,539€) [36]. The annual number of relapses was
lower in the glatiramer acetate cohort with 3.81 versus
4.18 in the interferon cohort and 4.08 in the cohort
treated with interferon plus glatiramer acetate. Results
from probabilistic sensitivity analysis showed that glatira-
mer acetate had a higher probability of being cost-
effective than the treatment with interferon or interferon





















The cost analyses are expressed in 2014 euros (€)
Fig. 1 Patients treated with a fixed budget
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plus glatiramer acetate for threshold values from 28,000€
onwards, independently of the maximum expense that the
Spanish National Health System is willing to pay for
avoiding relapses [36]. Glatiramer acetate was shown to be
a cost-effective treatment option to prevent relapses in
Spanish patients diagnosed with RRMS. When glatiramer
acetate monotherapy was compared with interferon
monotherapy and with interferon plus glatiramer acetate,
it might be concluded that the first was the dominant
strategy [36]. Even though comparison of economic evalua-
tions from other counties is always difficult due to differ-
ences in methodology, design, patient populations and
health systems, the data available supports the overall lower
costs of MS management with glatiramer acetate versus
interferon-β [38–45]. Recently, the large clinical cohort of
RRMS patients starting a DMT of the United Kingdom
Multiple Sclerosis Risk Sharing Scheme approached the
long-term disability progression and cost-effectiveness
of interferon-β and glatiramer acetate. The findings
from this observational study supported that the effects
of interferon-β and glatiramer acetate on disability in
RRMS patients were maintained and cost-effective even
over 6 years [46].
The lower acquisition cost of glatiramer acetate com-
pared to interferon-β may have contributed to the lower
costs reported in the previously mentioned analyses and
highlights the importance of efficient management of dis-
ease modifying therapies in the economic impact on the
health system. However, these evaluations did not quantify
the impact of spasticity, which may entail additional costs
such as those derived from the administration of spasmo-
lytic drugs. Our results support this hypothesis as spasticity
treatment during interferon-β accounted for approximately
148€ per patient and the spasticity improvement observed
after switching to glatiramer acetate enabled this figure to
be reduced by more than one-half.
Several analyses have reported that the costs of managing
MS are mainly driven by the utilization of healthcare
resources and the costs of disease modifying therapies
[7, 44, 45, 47]. However, a Spanish retrospective assess-
ment of MS patients with resistant spasticity also
pointed out this factor as a contributor to overall costs
of MS management, though to a lesser extent than dis-
ease modifying therapies and care provision [48]. Sub-
sequently, another Swedish study conducted in MS
patients with spasticity raised the issue of the substan-
tial burden of spasticity on the healthcare system, social
services, patients and relatives/caregivers [49]. This



















rate of 5 %
6,740.97€ 4,448.87€ 2,292.10€
The cost analyses are expressed in 2014 euros (€)
Fig. 2 Budget depending on the number of patients treated
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burden may increase over the course of MS and spasti-
city worsening, mainly driven by the increased need for
personal assistance and patient productivity losses [49].
A recently published online survey among health care
specialists in the management of MS and spasticity in
the United Kingdom also revealed the high impact of
spasticity on both health care resources and costs
according to the different levels of spasticity [50]. The
higher degrees of spasticity were associated with in-
creased need for clinic visits, accident and emergency
attendance, hospital admissions, district nurse support,
home care and specialised home equipment. This use
of resources was associated with additional costs that
increase as spasticity worsens, with a predominant impact
of increased home care, clinic visits and hospital admis-
sions to the overall annual costs in patients with more
severe spasticity. Therefore, any reduction in spasticity
achieved through either early or effective management of
spasticity could not only improve patients’ wellbeing but
may also lead to substantial cost savings [49, 50]. Further-
more, this survey provides additional insight into the com-
plexity of the economic implications of spasticity in MS,
which need to be carefully considered by national stake-
holders to ensure the sustainability of health systems.
The authors acknowledge that their economic analysis
has limitations that should be considered when inter-
preting its findings. Although prospective determination
of costs would be more appropriate for this type of stud-
ies [51], only was retrospective data available in the
Escala Study; therefore, limitations derived from the
availability of data should be considered. In addition, the
absence of a control group should be taken into account
and further controlled studies should be conducted to
avoid potentially confounding factors. Although the
study sample may look small, the sample size determin-
ation was based on a pilot study that evaluated the
effects of glatiramer acetate on spasticity in patients with
RRMS [18]. The scale with the lowest variation during
the study was considered to guarantee statistical signifi-
cance of the variable with the lowest change; the
selected variable was the ATRS, whose mean absolute
change ranged from 0.55 to 0.20, and the most conserva-
tive value (0.20) was used to calculate the sample size,
together with the standard deviation of patients previ-
ously treated with interferon-β (0.69) [24]. Nonetheless,
caution is advisable when interpreting the study findings
and additional larger studies would be desirable to achieve
confirmatory evidence on this matter. Moreover, potential
cost savings derived from the reduced number of patients
missing working days over glatiramer acetate—just five as
result of spasticity–[24] could not be considered due to
the lack of data on patients missing working days over
interferon-β; however, it can be hypothesized that spasti-
city improvements observed during glatiramer acetate
may lead to additional cost savings resulting from reduced
spasticity-related work leaves. Furthermore, this analysis
was conducted from the perspective of the National
Health System of Spain, taking into account only direct
healthcare costs and not considering indirect costs such
as loss of productivity. Nevertheless, the authors believe
that this analysis provides meaningful information on the
management of MS patients with spasticity in clinical
practice as it was based on real-life data instead of a litera-
ture review or expert opinion.
Conclusions
The administration of glatiramer acetate for RRMS
entailed cost savings after six months of treatment when
compared to interferon-β in patients with spasticity, which
not only resulted from its lower costs of therapy and re-
lapse management but also from its favourable effect on
reducing spasticity. The spasticity improvement observed
after switching from interferon-β to glatiramer acetate
may be accompanied by a cost reduction that might con-
tribute to the sustainability of our health system. Thus,
glatiramer acetate may be regarded as a more efficient al-
ternative than interferon-β from the perspective of the
National Health System of Spain. Nevertheless, our eco-
nomic analysis needs to be placed within the context of
the Escala Study and further larger long-term analyses are
still needed to confirm its findings, as well as providing
additional evidence on the impact of indirect costs and
differences in health systems between counties.
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